Начало・Списък с акции・Danaher Corp

Danaher Corp

Затворен

СекторЗдравеопазване

194.61 -1.46

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

192.43

Максимум

199.67

Ключови измерители
By Trading Economics
Приходи	-159M 870M
Продажби	314M 6.3B
P/E Средно за сектора	35.027 64.641
EPS	1.94
Дивидентна доходност	0.75
Марж на печалбата	13.887
Служители	58,000
EBITDA	-364M 1.1B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+11.28% upside

Дивиденти
By Acuity
Дивидентна доходност Средно за сектора	0.75% 2.31%
Следващи печалби	20.10.2026 г.
Следваща дата на дивидент	30.10.2026 г.
Следваща дата на екс-дивидент	25.09.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-4.2B 138B
Предишно отваряне	196.07
Предишно затваряне	194.61

Настроения в новините

By Acuity

50%

151 / 340 Класиране в Healthcare

Danaher Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 22:51 ч. UTC

News

Danaher Corp appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026. Shares are trading higher in after-market hours.

31.07.2026 г., 23:01 ч. UTC

Danaher Corp shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market weakness.

30.07.2026 г., 18:01 ч. UTC

Danaher Corp. shares are lower today, fluctuating within their one-month range amid volatility influenced by the Federal Reserve's interest rate decisions.

29.07.2026 г., 23:01 ч. UTC

Danaher Corp shares are higher in after-market trading, reflecting a slight increase since Wednesday's close. The stock reached a recent high shortly after 5:10 PM ET.

28.07.2026 г., 23:01 ч. UTC

Danaher Corp shares declined in after-hours trading amid broader market losses linked to concerns over artificial intelligence spending and competition from Chinese chipmakers.

27.07.2026 г., 23:16 ч. UTC

Danaher Corp shares are lower in after-market trading, declining slightly since Monday's close. No specific company news has been identified to explain the movement.

24.07.2026 г., 20:06 ч. UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23.07.2026 г., 10:01 ч. UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22.07.2026 г., 22:01 ч. UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21.07.2026 г., 19:41 ч. UTC

News

Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20.07.2026 г., 23:41 ч. UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Сравнение с други в отрасъла

Ценова промяна

Danaher Corp Прогноза

Ценова цел

By TipRanks

11.28% нагоре

12-месечна прогноза

Среден 219.78 USD 11.28%

Висок 240 USD

Нисък 195 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Danaher Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Danaher Corp през последните 3 месеца.

Настроение

By Acuity

151 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.